What records are connected here?
- Evidence lanes
- 3
- Source years
- 15
- Drugs@FDA applications
- 11
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsInflammation and immune
Icatibant is a synthetic decapeptide that blocks the bradykinin B2 receptor, and the active ingredient in Firazyr.1,2 FDA approved Firazyr in 2011 to treat acute attacks of hereditary angioedema (HAE), a genetic condition that causes episodes of severe swelling, in adults.1,2 In a randomized, placebo-controlled trial, symptoms halved in a median of 2.0 hours with icatibant versus 19.8 hours with placebo, according to the label.1
| What it is | A synthetic decapeptide containing five non-standard amino acids that competitively blocks the bradykinin B2 receptor, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Firazyr with an original approval date of August 25, 2011. The cited label has no boxed warning.1,2 |
| Human evidence | Three controlled trials in 223 adults with acute HAE attacks, including a randomized, double-blind, placebo-controlled trial in 98 adults, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Icatibant is a synthetic peptide of ten amino acids, five of which are not found in natural proteins, according to the label.1
In the United States it is the active ingredient of Firazyr, from Takeda, according to Drugs@FDA.2
The label explains that HAE is caused by missing or faulty C1-esterase inhibitor, which leads to excess bradykinin, a substance thought to cause the swelling, inflammation and pain of attacks.1
Icatibant is a selective, competitive blocker of the bradykinin B2 receptor and stops bradykinin from binding it, according to the label.1
In Trial 1, a randomized, double-blind, placebo-controlled trial, the median time to a 50% reduction in skin and abdominal symptoms was 2.0 hours with icatibant (43 patients) and 19.8 hours with placebo (45 patients), according to the label.1
In the same trial, 7% of patients on icatibant and 40% on placebo used additional rescue medication, according to the label.1
Across the three controlled trials, the median time to a 50% reduction in symptoms ranged from 2.0 to 2.3 hours, and results for throat (laryngeal) attacks were similar, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Firazyr, application NDA 022150, with an original approval date of August 25, 2011.2
The Firazyr label cited here (DailyMed SPL version 19, published July 17, 2025) states that it is indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.1
The label has no boxed warning and lists no contraindications. It warns that after treatment of a throat attack, patients should seek immediate medical attention because of the risk of airway obstruction.1
Its use in children, since the approved indication in the label covers adults 18 and older.1
Whether it prevents attacks: the label covers treatment of acute attacks, not prevention.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Icatibant: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Icatibant are a bounded selection, not every registration or paper about Icatibant. For the years before Icatibant was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Icatibant as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Icatibant in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Firazyr for acute attacks of hereditary angioedema. Controlled trials described in the label, including a randomized, placebo-controlled trial of 98 adults, found faster symptom relief with icatibant.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Firazyr for acute attacks of hereditary angioedema. Controlled trials described in the label, including a randomized, placebo-controlled trial of 98 adults, found faster symptom relief with icatibant.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 8, 2026
Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.↗Source date November 8, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT05834777↗Source date October 22, 2026Literature metadata · added November 15, 2026
On-demand treatment of icatibant in a patient of hereditary angioedema with KNG1 mutation.↗Source date August 28, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
17 of 19 selected trial records include at least one phase value; 19 of 19 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00097695 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00223704 at 2026-11-15T22:04:12.435Z. Its registry update date was 2013-11-25, and PeptideScanner's reviewed identity mapping was icatibant.
PeptideScanner retained ClinicalTrials.gov record NCT00500656 at 2026-11-15T22:04:12.435Z. Its registry update date was 2021-06-09, and PeptideScanner's reviewed identity mapping was icatibant.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 21, 2007 to November 8, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 24749847 in Clinical and experimental immunology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, and 1 more PubMed publication type, with publication-date metadata of 2014-08 (month precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05834777 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was icatibant.↗
Literature metadata
PubMed lists PMID 42656409 in Genes & diseases as Editorial, with publication-date metadata of 2026-05-14 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04113109 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was icatibant.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05509569 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was icatibant.↗
Literature metadata
PubMed lists PMID 42219034 in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases as Journal Article, Case Reports, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42343494 in Allergy and asthma proceedings as Journal Article, Systematic Review, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41008531 in Biomolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-25 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04488081 at 2026-11-15T22:04:12.435Z. Its registry update date was 2026-03-16, and PeptideScanner's reviewed identity mapping was icatibant.↗
Literature metadata
PubMed lists PMID 36641883 in Journal of photochemistry and photobiology. B, Biology as Journal Article, with publication-date metadata of 2023-01-10 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37067851 in Infectious diseases (London, England) as Letter, Comment, with publication-date metadata of 2023-04-17 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38142950 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, with publication-date metadata of 2023-12-22 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026